trending Market Intelligence /marketintelligence/en/news-insights/trending/6adLYu4V6XA572xILx6ruA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Arrowhead raises $266.8M via common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Arrowhead raises $266.8M via common stock offering

Arrowhead Pharmaceuticals Inc. raised about $266.8 million in gross proceeds via a public offering of its common shares.

The biotechnology company sold 4.6 million shares at $58 apiece, including 600,000 additional shares as part of underwriters' overallotment option.

The Pasadena, Calif.-based company, that develops therapies for the treatment of rare genetic disorders, plans to use the net proceeds from the offering for research and development activities. Funds will also be used for the acquisition of complementary businesses, products and technologies.

Goldman Sachs & Co. LLC, Jefferies LLC and Piper Jaffray & Co. were the book-running managers for the offering, while Cantor Fitzgerald & Co. acted as a passive joint book runner, and Robert W. Baird & Co. Inc. and B. Riley FBR Inc. acted as co-managers.